Nod Scid Mouse
Nod Scid Mouse - Related Videos
07:10
Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
0 Views •
Cited by 13 •
2019
This protocol provides a method to establish humanized mice (hu-NSG) via intrahepatic injection of human hematopoietic stem cells into radiation-conditioned neonatal NSG mice. The hu-NSG mouse is susceptible to HIV infection and combinatorial antiretroviral therapy (cART) and serves as a suitable pathophysiological model for HIV replication and latency investigations.
04:16
Imaging Transgenic Beta-Cells in an Immunodeficient Mouse Challenged with Diabetic Splenocytes
0 Views •
2025
This video demonstrates an imaging-based method to visualize transplanted luciferase-expressing beta cells into a non-obese diabetic immunodeficient mouse. The introduction of splenocytes from a diabetic mouse leads to progressive beta cell destruction, visually confirmed by declining luminescence after substrate introduction.
02:26
A Technique to Generate a Human PBMC-Engrafted Humanized Xenograft Mouse Model
0 Views •
2025
This video demonstrates an assay to generate a humanized xenograft mouse model. An immunocompromised mouse is injected with cyclophosphamide to cause immune cell depletion. Patient-derived tumor cells mixed with human peripheral blood mononuclear cells (PBMCs) in a hydrogel are subcutaneously injected into the mouse, forming a tumor with infiltrating T cells.
03:32
Patient-derived Tumor Xenografting: A Technique to Generate Experimental Mouse Model for Evaluating Urothelial Cell Carcinoma
0 Views •
2023
This video describes the procedure to generate an experimental xenograft murine model, which can be used for studying urothelial cell carcinoma progression.
03:19
Generating PDOX Mouse Model of Colorectal Cancer: Studying Progression of Colorectal Cancer in a Murine Model
0 Views •
2023
This video describes the protocol for generating a patient-derived orthotopic xenograft colorectal cancer mouse model to study the progression of colorectal cancer cells in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. This murine model helps in understanding primary tumor growth and metastases pattern.
FAQs
The model’s two genetic features weaken different parts of host immunity. The NOD background impairs innate immune function, while the scid mutation blocks development of functional T and B lymphocytes. Acting together, these defects reduce immune rejection of transplanted human cells, tissues, or tumors. This complementary immunodeficiency makes the mouse suitable for in vivo human-material studies.
Because transplanted human material can otherwise be rejected, the combined immune defects create a host more permissive to human tumor xenografts. That allows investigators to examine tumor behavior in a living system and test anticancer treatments against human-derived material. The resulting observations can provide preclinical evidence while retaining the need for careful model-specific interpretation.
Studies in this model can focus on whether a human tumor grows, how it behaves in relation to metastasis, and how it responds to an anticancer therapy. These endpoints connect the xenograft to practical cancer-research questions: characterizing tumor progression and generating preclinical evidence about treatment effects in an in vivo setting.
The central workflow is to place human cells, tissues, or tumor material into the mouse and then use the resulting xenograft system for in vivo investigation. The source context supports this as a platform for studying tumor growth, metastasis, and therapy evaluation, but it does not specify implantation site, dose, timing, or measurement protocol.
Researchers would select this model when they need to study human tumor biology in vivo or evaluate an anticancer therapy using human-derived tumor material. Its value is greatest for questions involving tumor growth, metastatic behavior, or treatment response, where observations in a living host can supplement other cancer-research approaches with preclinical evidence.
Results require model-specific interpretation because the same immune defects that permit human-material transplantation also make the host unlike an immunologically intact setting. Findings therefore provide preclinical evidence about tumor biology or therapy in this particular model, not a complete representation of cancer behavior under all immune conditions.